Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
NCT ID: NCT01826370
Last Updated: 2014-09-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
678 participants
OBSERVATIONAL
2012-05-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet
NCT01383356
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
NCT01512979
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
NCT01012037
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
NCT00309608
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
NCT01215097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Linagliptin
Linagliptin
tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Linagliptin
tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient using Linagliptin within label or locally approved indication. The prescription of Linagliptin to the patient must be in the course of normal clinical practice and independent of the decision to include the patient in the study.
3. Male or female patients more than 18 years old
4. Body mass index less than or equal to 40
5. Diagnosed with type 2 DM
6. Uncontrolled type 2 DM with fasting blood sugar of more than 126 mg/dl and/or HbA1c more than 7%.
Exclusion Criteria
2. Patients with acute illness requiring hospitalization in the past one month
3. Patients participating in a different study that includes an investigational drug
4. Patients with known hypersensitivity reaction to Linagliptin or any of tis components
5. Pregnant women and those women who have intentions of getting pregnant within the study duration
6. Nursing women
7. Patients with concomitant conditions that contraindicates Linagliptin use as described in its product information
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site 43
Agoo, La Union, , Philippines
Boehringer Ingelheim Investigational Site 40
Angeles City, Pampanga, , Philippines
Boehringer Ingelheim Investigational Site 31
Angono, Rizal, , Philippines
Boehringer Ingelheim Investigational Site 32
Antipolo, Rizal, , Philippines
Boehringer Ingelheim Investigational Site 27
Aparri, Cagayan, , Philippines
Boehringer Ingelheim Investigational Site 4
Batangas, , Philippines
Boehringer Ingelheim Investigational Site 48
Butuan City, Agusan Del Norte, , Philippines
Boehringer Ingelheim Investigational Site 12
Cabanatuan, Nueva Ecija, , Philippines
Boehringer Ingelheim Investigational Site 23
Cagayan de Oro, , Philippines
Boehringer Ingelheim Investigational Site 3
Caloocan, , Philippines
Boehringer Ingelheim Investigational Site 42
Cardona, Rizal, , Philippines
Boehringer Ingelheim Investigational Site 25
Cebu, , Philippines
Boehringer Ingelheim Investigational Site 44
Dagupan, Pangasinan, , Philippines
Boehringer Ingelheim Investigational Site 49
Iligan City, Lanao Del Norte, , Philippines
Boehringer Ingelheim Investigational Site 2
Iloilo City, , Philippines
Boehringer Ingelheim Investigational Site 45
Iriga City, Camarines Sur, , Philippines
Boehringer Ingelheim Investigational Site 20
Laoag, Ilocos Norte, , Philippines
Boehringer Ingelheim Investigational Site 24
Las Piñas, , Philippines
Boehringer Ingelheim Investigational Site 7
Legazpi, Albay, , Philippines
Boehringer Ingelheim Investigational Site 35
Lucena, Quezon, , Philippines
Boehringer Ingelheim Investigational Site 1
Makati, , Philippines
Boehringer Ingelheim Investigational Site 39
Malolos, Bulacan, , Philippines
Boehringer Ingelheim Investigational Site 37
Mandaluyong, , Philippines
Boehringer Ingelheim Investigational Site 28
Manila, , Philippines
Boehringer Ingelheim Investigational Site 5
Marikina City, , Philippines
Boehringer Ingelheim Investigational Site 16
Meycauyan, Bulacan, , Philippines
Boehringer Ingelheim Investigational Site 47
Naga City, Camarines Sur, , Philippines
Boehringer Ingelheim Investigational Site 15
Olongapo City, , Philippines
Boehringer Ingelheim Investigational Site 10
Pampanga, , Philippines
Boehringer Ingelheim Investigational Site 19
Paranaque City, , Philippines
Boehringer Ingelheim Investigational Site 51
Pasay, , Philippines
Boehringer Ingelheim Investigational Site 30
Pasig, , Philippines
Boehringer Ingelheim Investigational Site 34
Puerto Princesa, Palawan, , Philippines
Boehringer Ingelheim Investigational Site 26
Quezon City, , Philippines
Boehringer Ingelheim Investigational Site 11
Rosales, Pangasinan, , Philippines
Boehringer Ingelheim Investigational Site 21
San Fernando, La Union, , Philippines
Boehringer Ingelheim Investigational Site 9
San Fernando, Pampanga, , Philippines
Boehringer Ingelheim Investigational Site 13
San Jose, Nueva Ecija, , Philippines
Boehringer Ingelheim Investigational Site 29
San Juan City, , Philippines
Boehringer Ingelheim Investigational Site 8
San Pablo, Laguna, , Philippines
Boehringer Ingelheim Investigational Site 50
San Pedro, Laguna, , Philippines
Boehringer Ingelheim Investigational Site 41
Santiago City, Isabela, , Philippines
Boehringer Ingelheim Investigational Site 36
Sogod, Southern Leyte, , Philippines
Boehringer Ingelheim Investigational Site 38
Sta.Maria, Bulacan, , Philippines
Boehringer Ingelheim Investigational Site 6
Tacloban City, , Philippines
Boehringer Ingelheim Investigational Site 33
Tagbilaran, Bohol, , Philippines
Boehringer Ingelheim Investigational Site 14
Tuguegarao, Cagayan, , Philippines
Boehringer Ingelheim Investigational Site 18
Urdaneta, Pangasinan, , Philippines
Boehringer Ingelheim Investigational Site 46
Valencia City Bukidnon, , Philippines
Boehringer Ingelheim Investigational Site 17
Valenzuela, Bulacan, , Philippines
Boehringer Ingelheim Investigational Site 22
Zamboanga City, , Philippines
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1218.94
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.